DDInter1124 DDInter1376
Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Maprotiline {u} (Compound) resembles {v} (Compound) Protriptyline
Maprotiline {u} (Compound) resembles {v} (Compound) Demexiptiline
Maprotiline {u} (Compound) binds {v} (Gene) ABCB1
Maprotiline {u} (Compound) upregulates {v} (Gene) UBE2L6
Maprotiline {u} (Compound) palliates {v} (Disease) panic disorder
Maprotiline {u} (Compound) downregulates {v} (Gene) CCNA2
Maprotiline {u} (Compound) causes {v} (Side Effect) Angiopathy
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Maprotiline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ephedrine
Maprotiline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sunitinib
Maprotiline (Compound) resembles Protriptyline (Compound)
Maprotiline (Compound) resembles Demexiptiline (Compound)
Maprotiline (Compound) binds ABCB1 (Gene)
Maprotiline (Compound) upregulates UBE2L6 (Gene)
Maprotiline (Compound) palliates panic disorder (Disease)
Maprotiline (Compound) downregulates CCNA2 (Gene)
Maprotiline (Compound) causes Angiopathy (Side Effect)
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Maprotiline may cause a minor interaction that can limit clinical effects when taken with Ephedrine
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib